Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Utidelone Capsules (UTD2) Combined With Doxorubicin for Advanced Soft Tissue Sarcoma

NCT07842276 is registered in ClinicalTrials.gov with Beijing Biostar Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07842276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Utidelone Capsules (UTD2) Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 18, 2026
Completion date
December 20, 2028
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

doxorubicin, soft tissue sarcoma (sts), utidelone